AMT-253 in Patients With Advanced Solid Tumours
A phase 1/2 trial of AMT-253 for injection in melanoma, run by Multitude Therapeutics Inc., now recruiting.
Overview
AMT-253 in Patients With Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06209580 by Multitude Therapeutics Inc., with 96 participants planned, started 2024-01-31 and due to reach its primary completion in 2026-04-30. Interventions recorded: AMT-253 for injection.
Setting
Phase I/II Study of AMT-253 in Patients With Unresectable or Metastatic Malignant Melanoma and Other Advanced Solid Tumors
Phase
Phase 1/2
Sponsor
Multitude Therapeutics Inc.
Registry
Enrolled
96
Similar pages
not linked directly; found by shared links- TrialAMT-116 in Patients with Solid Tumors
Shares Multitude Therapeutics and the tag pipeline.
- TrialPhase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
Shares Melanoma and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.
- TrialNeoadjuvant L19IL2/L19TNF- Pivotal Study
Shares Melanoma and the tag pipeline.
- TrialEfficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
Shares Melanoma and the tag pipeline.
- TrialSCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
Shares Melanoma and the tag pipeline.
- TrialA Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Shares Melanoma and the tag pipeline.
- TrialSafety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.